Financing, Equity Capital Markets

Keros Therapeutics

01/24
|
$161.0 Million
Keros
Piper Sandler served as bookrunner for Keros Therapeutics, Inc. on a confidentially marketed follow-on offering
Sub-Type
Confidentially Marketed Follow-On Offering
Sub-Sector
Biopharma